Ron Ben-Menachem

CHOOSE BY ALPHABET

A | B | C | D | E | F | G | H | J | K | L | M | N | O | P | R | S | T | V | W | Y | Z

Profile

Ron Ben-Menachem is a partner in the Corporate and Securities Departments. His practice focuses on private and public offerings and mergers and acquisitions, with a special emphasis on international transactions. Ron represents domestic and foreign clients in a broad range of industries, including financial services, technology, pharmaceuticals, energy and consumer products.

Ron is rated as a "Leading Lawyer" by the International Financial Law Review (IFLR). 

Ron is the winner of the 2016 Deal Maker of the Year Award for his work on the $22 Billion notes offering by Teva Pharmaceuticls Industries, awarded by Finance Monthly magazine.

Ron is a winner of the 2013 Deal Maker of the Year Award for his work on the $1.4 billion global notes offering by Israel Electric Corporation awarded by Finance Monthly magazine.

Prior to joining HFN, Ron practiced corporate law with the New York office of Weil, Gotshal & Manges LLP (2004-2011) and clerked for the Honorable Justice Edmund E. Levy, Israel Supreme Court (2001).

Representative Transactions:

  • Lead counsel to Elbit Systems in a $185,000,000 offering conducted as a PIPE and listing on Nasdaq.
  • Representing Cellcom Israel (NYSE: CEL), a dually-listed company, in connection with their capital markets activitiesץ
  • Represented WeWork in its acquisition of Unomy Ltd.
  • Representing Aspire Global in its IPO on Nasdaq North (Stockholm).
  • Represented Mellanox Technologies in its $811 million acquisition of EZchip Semiconductors.
  • Israeli counsel to a consortium of 10 banks, led by Barclays, Bank of America Merrill Lynch, Credit Suisse and HSBC in the public offering of Teva Pharmaceuticals Industries. Totalling $6.75 billion that was the largest equity offering by an Israeli company.
  • Israeli counsel to a consortium of banks, led by Barclays, Bank of America Merrill Lynch, Credit Suisse and HSBC in three public offerings of Teva Pharmaceuticals Industries, with an aggregate proceeds of approximately $22 billion. These offerings constitute the largest offerings ever by an Israeli company.
  • Representing Israel Electric Corporation in its 144/Reg S. public debt offerings: $1.4 billion in November 2014; $1.1 billion in June 2013; $500 million in February 2012.
  • Israeli counsel to Varonis Systems in its $105 million IPO on NASDAQ.
  • Representing Magic Software Enterprises in its $60 million public offering on NASDAQ.
  • Representing Foamix Pharmaceuticals in its $70 million public follow-on offering (September 2018), $60 million public follow-on offering (April 2015) and its shelf registration in an amount of up to $150 million (October 2015), and with respect to their ongoing SEC reporting and compliance matters.
  • Israeli counsel to Imperva Inc. in connection with its $135 million follow-on offering on NYSE.
  • Israeli counsel to William Blair as underwriters of a $20 million public offering by RadCom on NASDAQ.
  • Israeli counsel to William Blair as underwriters in a $32 million public offering of AudioCodes Ltd. on NASDAQ.
  • Israeli counsel to Pfizer in the Spin-off of its animal health business, Zoetis.
  • Israeli counsel to Abbott Laboratories in the Spin-off of its research-based pharmaceutical business, Abbvie.
  • Representing Noy Infrastructure and Energy Fund in its investment in Metronit, Haifa’s light rail mass transit system.
  • Representing WeWork in their affairs in Israel. 

Education

  • Columbia Law School, New York, LL.M (with honors), 2004
  • The Interdisciplinary Center (IDC), Herzliya, Israel, LL.B (with honors), 2000
  • The Interdisciplinary Center (IDC), Herzliya, Israel, BA (Business Administration & Finance) ,(with honors), 2000

Admitted to Practice

Country: 

New York

Year: 

2005

Country: 

Israel

Year: 

2001